Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ: MRNA )

32.99 +1.07 (+3.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
3 No-Brainer Healthcare Stocks to Buy Right Now
These players have what it takes to boost your portfolio over time. 
Via The Motley Fool
Fear & Greed Index Remains In 'Greed' Zone Following Economic Reports; Dow Records New High
The CNN Money Fear and Greed index showed some easing in overall market sentiment, but the index remained in the "Greed" zone on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Costco, Pfizer, Moderna, Lennar Corp, Tesla: Why These 5 Stocks Are On Investors' Radars Today
The stock market witnessed a notable surge today, with the Dow Jones rising 0.43% to 37,248.35 and the S&P 500 gaining 0.26% to 4,719.55. 
Via Benzinga
Topics Stocks
Exposures US Equities
MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer
Moderna is in focus after reporting positive results for its cancer treatment today, with MRNA stock surging more than 9%. 
Via InvestorPlace
Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted'
Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's promising new cancer vaccine developed in 
Via Benzinga
2 Big Stocks Making Big Moves Thursday
One is rising while the other's on the decline. Here's why. 
Via The Motley Fool
What's Going On With Moderna (MRNA) Stock?
Moderna Inc (NASDAQ: MRNA) shares are trading lower by 4.5% to $74.50 during Wednesday's session. 
Via Benzinga
Moderna's Options Frenzy: What You Need to Know
Via Benzinga
Nasdaq Turns Lower; US Retail Sales Top Estimates
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.04% to 37,105.00 while the NASDAQ fell 0.44% to 14,669.25. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Eye 7-Day Winning Streak As Mortgage Rates Fall Below 7%, Yields Tumble: What's Driving Markets Thursday?
It’s shaping up to be a positive Thursday on Wall Street, with risk sentiment remaining robust after the Federal Reserve effectively opened the door to rate cuts in 2024. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
Via ACCESSWIRE
Why Are Bank Stocks Up Today?
Bank stocks are up today and investors wonder why have come to the right place as we have a detailed explanation for the rally! 
Via InvestorPlace
Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales... 
Via Benzinga
Jabil Posts Upbeat Earnings, Joins Moderna, Rivian Automotive And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is SOFI Stock Up Today?
SoFi Technologies stock is up on Thursday as investors celebrate news that the Federal Reserve won't increase interest rates. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Opendoor (OPEN) Stock Jumps on Analyst Upgrade
Opendoor Technologies stock is rising higher on Thursday as investors in OPEN shares react to an upgrade from Keefe, Bruyette & Woods. 
Via InvestorPlace
Why Is Moderna (MRNA) Stock Up 11% Today?
Moderna stock is on the rise Thursday as investors in MRNA react to positive results from a skin cancer vaccine in a Phase 2b trial. 
Via InvestorPlace
Moderna Stock Is Soaring Today - Here's Why
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940), an investigational individualized... 
Via Benzinga
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
Via ACCESSWIRE
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday?
Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Pfizer Issues FY24 Forecast, Joins Target Hospitality, Southwest Airlines And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Shares of Pfizer Inc. (NYSE: PFE) shares fell sharply during Wednesday’s session after the company... 
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints
Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target. 
Via Investor's Business Daily
3 Dirt-Cheap Stocks to Buy Hand Over Fist Before the End of the Year
These players could lift your portfolio when they rebound and over the long term. 
Via The Motley Fool
What's Going On With Moderna Stock Today?
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and  
Via Benzinga
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
Via ACCESSWIRE
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
These 2 Stocks Are All-Stars in the Making
These exciting players look cheap today considering their future prospects. 
Via The Motley Fool
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
The big biotech's shares have been on the rise this year. 
Via The Motley Fool
7 F-Rated Stocks to Sell in December
If you’re holding F-rated stocks to sell, it may be too late to salvage 2023, but you can still get back on track toward achieving your goals. 
Via InvestorPlace
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%). 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.